Zipalertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in First-Line EGFR Exon 20 Insertion-Positive NSCLC
Phase 3positivezipalertinibplatinum-pemetrexed chemotherapyPositive
AI Analysis
Summary
Phase 3 REZILIENT 3 trial demonstrates that zipalertinib combined with platinum-pemetrexed chemotherapy significantly extends progression-free survival and improves response rates in first-line treatment of EGFR Exon 20 Insertion-Positive NSCLC, with a six-month median PFS improvement.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
REZILIENT 3 trial showed zipalertinib plus platinum-pemetrexed chemotherapy significantly improved progression-free survival with a six-month improvement in median PFS and higher response rates in first-line EGFR Exon 20 Insertion-Positive NSCLC
Importance:8/10
Sentiment:
0.80
NSCLConcologyPhase 3EGFR mutationcombination therapyprogression-free survival
Read the original article
Published by PR Newswire Pharma on September 14, 2026 3:29 PM